Related Experiment Video
Updated: Jun 3, 2026
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
Targeting the endocannabinod system to limit myocardial and cerebral ischemic and reperfusion injury
Ronald F Tuma1, Sabine Steffens
1Center for Substance Abuse Research and Department of Physiology, Temple University, School of Medicine, Philadelphia, PA, USA.
Insights
Targeting the endocannabinoid system may offer a novel therapeutic strategy for myocardial infarction and ischemic stroke. This approach could mitigate reperfusion injury by reducing inflammation, oxidative stress, and excitotoxicity.
Area of Science:
- Cardiovascular Research
- Neuroscience
- Pharmacology
Background:
- Myocardial and cerebral infarction, caused by arterial occlusion, are leading global causes of death.
- Reperfusion therapy, while vital for salvaging ischemic organs, can paradoxically cause further damage (reperfusion injury).
- Previous therapeutic strategies targeting single mediators of reperfusion injury have shown limited clinical success.
Purpose of the Study:
- To review the role of cannabinoid and endocannabinoid systems in myocardial infarction and ischemic stroke.
- To explore the potential of targeting the endocannabinoid system as a novel therapeutic strategy.
- To discuss the mechanisms by which the endocannabinoid system influences these conditions.
Main Methods:
- Literature review of experimental studies on cannabinoid and endocannabinoid effects.
- Analysis of mechanisms involved in myocardial infarction, reperfusion injury, and ischemic stroke.
- Examination of evidence for therapeutic targeting of the endocannabinoid system.
Main Results:
- The endocannabinoid system plays a complex role in the pathogenesis of myocardial infarction and ischemic stroke.
- Experimental evidence suggests targeting this system can reduce inflammation, oxidative stress, fibrosis, and excitotoxicity.
- Enhanced blood flow is another potential benefit observed in studies.
Conclusions:
- Targeting the endocannabinoid system presents a promising novel therapeutic avenue for acute vascular events.
- This approach may limit the damage from myocardial infarction and ischemic stroke, including reperfusion injury.
- Further research into the endocannabinoid system could lead to improved treatments for these life-threatening conditions.
Abstract:
Coronary and carotid arterial occlusion due to thrombosis after atherosclerotic plaque rupture is the major cause of myocardial and cerebral infarction. Together these acute events represent the leading cause of death worldwide. Early reperfusion is the best method to salvage the ischemic organ; however, it leads to additional damage known as reperfusion injury. A large number of experimental studies has been performed in the past aimed at targeting individual mediators of reperfusion injury such as treatment with anti-oxidants or anti-inflammatory agents. Although many agents proved beneficial in animal models of myocardial or cerebral ischemia/reperfusion, the attempts to translate these protective effects into clinical practice were mostly disappointing. Elucidating the complex cellular and molecular mechanisms involved in ischemic cell death is crucial for the development of more efficient drugs in order to improve current treatment strategies. The aim of this review is to discuss cannabinoid and endocannabinoid-mediated effects in the pathogenesis of myocardial infarction and reperfusion injury, post-myocardial infarction remodeling, as well as ischemic stroke and reperfusion injury. We report experimental evidence suggesting that targeting the endocannabinoid system might evolve as a novel therapeutic concept to limit the devastating consequences of these acute vascular events through a wide variety of mechanisms, including lowering inflammation, oxidative stress, fibrosis, and excitotoxicity, and enhanced blood flow.
